After 21 months of follow-up in the SWEFOT trial, improvements in quality of life were similar in patients with methotrexate-resistant early rheumatoid arthritis (RA) who received infliximab (n = 128) or sulfasalazine and hydroxychloroquine (n = 130) in addition to continued methotrexate therapy. No between-group difference was detected in either EuroQol 5-Dimensions utility score or the number of quality-adjusted life-years.
ORIGINAL RESEARCH PAPER
Karlsson, J. A. et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202062
Rights and permissions
About this article
Cite this article
SWEFOT quality-of-life results show no benefit of infliximab. Nat Rev Rheumatol 9, 64 (2013). https://doi.org/10.1038/nrrheum.2012.228
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.228
